Related Experiment Videos
Streptokinase and tissue plasminogen activator in acute myocardial infarction
Insights
Thrombolytic therapy, including streptokinase (SK), is increasingly used for myocardial infarction, showing short-term mortality benefits. Further research is needed on long-term outcomes and optimal post-therapy management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Thrombolytic agents are increasingly utilized for acute myocardial infarction treatment.
- Community hospitals commonly use intravenous streptokinase (SK), while cardiac catheterization labs may use intracoronary SK and angioplasty.
- Tissue plasminogen activator is under extensive clinical investigation.
Purpose of the Study:
- To review the current use and documented benefits of thrombolytic therapy in myocardial infarction.
- To highlight the impact of major trials like GISSI and the Netherlands trial on understanding thrombolytic efficacy.
- To emphasize the need for early patient presentation and further research into long-term outcomes.
Main Methods:
- Review of clinical trials and existing literature on thrombolytic therapy for myocardial infarction.
- Analysis of data from large-scale trials such as GISSI and the Netherlands trial.
- Synthesis of reported benefits including improved ejection fraction, regional wall motion, and mortality reduction.
Main Results:
- Thrombolytic therapy, specifically SK, has demonstrated significant short-term mortality reduction in myocardial infarction patients.
- Benefits include increased ejection fraction and improved regional wall motion.
- Large trials (GISSI, Netherlands) confirm short-term survival advantages compared to control groups.
Conclusions:
- Thrombolytic therapy is an evolving treatment for acute myocardial infarction with proven short-term benefits.
- Increased awareness and early patient intervention are crucial for maximizing myocardial salvage.
- Long-term prognosis and optimal post-thrombolytic management require further investigation.
Abstract:
The use of thrombolytic agents for the treatment of myocardial infarction is increasing. Many community hospitals are infusing SK intravenously and those with cardiac catheterization laboratories often use intracoronary SK and angioplasty. Tissue plasminogen activator is undergoing extensive clinical trials, and reports of this research should add to our knowledge of this new therapy. Recently, benefits from thrombolytic therapy such as increased ejection fraction, improved regional wall motion, and short-term decreases in mortality have been documented. Both the GISSI trial that recruited 11,712 patients in Italy and the Netherlands trial documented significant short-term decreases in mortality after therapy with SK compared with control groups. As this information reaches the medical community, we may see an increase in the use of thrombolytic therapy during acute myocardial infarction. Additionally, community education service organizations should reemphasize the importance of seeking help early after the signs and symptoms of acute myocardial infarction appear to promote early treatment and potential salvage of greater amounts of myocardium. The long-term prognosis of patients who have been successfully reperfused and the best management after thrombolytic therapy is not yet known. Future problems and benefits from this therapy are still to be determined.